In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Reichert Technologies Inc.

Latest From Reichert Technologies Inc.

Deals In Depth: October 2011

October’s dealmaking highlights: Biogen received exclusive global rights to Portola’s autoimmune and anti-inflammatory Syk inhibitors in an alliance worth $554 million. Investment firms took public CRO Pharmaceutical Product Development private for $33.25 per share, or a total of $3.9 billion, including debt. Regeneron’s $391 million notes sale propelled the debt category to claim almost half of the $826 million biopharma financing figure. Meantime device companies raised $206 million, mainly from Zeltiq’s $93 million IPO.

BioPharmaceutical Medical Device

Deals Update

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Medical Device
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Other Names / Subsidiaries
    • Reichert Inc.